Chief Medical Officer · Lyell Immunopharma, Inc. · Lyell Immunopharma, Inc. — Option (right to buy)
Side
A
Value
—
Shares
47.5K
Price
—
Executed
Sep 10, 2026
Disclosed
Sep 10, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Sep 10 executedSep 10, 2026 disclosed
LYEL · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 0 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Aguirre Jarrad Mattieu filed this Form 4 reporting a grant or award of LYEL on Sep 10, 2026. It became public on Sep 10, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Medical Officer
Aguirre Jarrad Mattieucik:0002150331
Issuer
Lyell Immunopharma, Inc.cik:0001806952
Revision history · 0
No field has changed since this record was first ingested.
